IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.000
AS - Asia 4.723
EU - Europa 4.536
SA - Sud America 1.004
AF - Africa 147
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 10
Totale 17.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.813
SG - Singapore 2.103
CN - Cina 1.219
DE - Germania 1.204
BR - Brasile 778
SE - Svezia 745
IT - Italia 497
UA - Ucraina 432
FR - Francia 422
VN - Vietnam 380
GB - Regno Unito 238
IE - Irlanda 231
PL - Polonia 210
IN - India 185
FI - Finlandia 154
ID - Indonesia 149
RU - Federazione Russa 128
JP - Giappone 127
BD - Bangladesh 113
HK - Hong Kong 95
CA - Canada 85
TR - Turchia 85
AR - Argentina 62
MX - Messico 55
IQ - Iraq 54
EC - Ecuador 48
NL - Olanda 48
BE - Belgio 46
ES - Italia 43
CI - Costa d'Avorio 35
CL - Cile 33
PK - Pakistan 32
ZA - Sudafrica 30
AT - Austria 28
VE - Venezuela 26
RO - Romania 22
KE - Kenya 21
CO - Colombia 20
IL - Israele 20
UZ - Uzbekistan 20
AU - Australia 19
PE - Perù 17
SA - Arabia Saudita 17
KR - Corea 14
JO - Giordania 12
LT - Lituania 12
OM - Oman 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
EG - Egitto 11
MA - Marocco 11
TN - Tunisia 11
AZ - Azerbaigian 10
BG - Bulgaria 10
PY - Paraguay 10
IR - Iran 9
CR - Costa Rica 8
DZ - Algeria 8
MY - Malesia 8
CZ - Repubblica Ceca 7
GR - Grecia 7
BZ - Belize 6
PH - Filippine 6
PT - Portogallo 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
JM - Giamaica 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
PR - Porto Rico 5
UY - Uruguay 5
AO - Angola 4
BO - Bolivia 4
DK - Danimarca 4
EU - Europa 4
HN - Honduras 4
HU - Ungheria 4
LK - Sri Lanka 4
LU - Lussemburgo 4
NI - Nicaragua 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
BB - Barbados 2
CY - Cipro 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
Totale 17.416
Salva come PNG Salva come JPEG
Città #
Singapore 1.113
Chandler 891
Ashburn 811
San Jose 584
Jacksonville 286
Beijing 251
San Mateo 230
Dublin 221
New York 208
Warsaw 174
Wilmington 156
Ann Arbor 154
Nanjing 141
Los Angeles 136
Houston 135
Jakarta 135
Ho Chi Minh City 126
Lauterbourg 125
Dearborn 116
Woodbridge 114
Boston 104
Tokyo 99
Cattolica 96
Hanoi 96
Hong Kong 92
Chicago 89
Dallas 85
Frankfurt am Main 81
Hefei 80
Princeton 71
Milan 70
Redwood City 69
São Paulo 68
Moscow 66
Lawrence 61
Cambridge 58
North Bergen 57
Seattle 54
Nürnberg 53
Rome 53
Buffalo 51
Santa Clara 51
Marseille 50
Munich 50
Fairfield 49
Bremen 46
Izmir 46
Nanchang 45
Fuzhou 42
London 42
Hangzhou 41
Brussels 38
Shanghai 38
Redmond 37
Abidjan 35
Nuremberg 34
Tianjin 31
Mountain View 30
Boardman 29
Helsinki 28
Council Bluffs 27
Shenyang 27
Zhengzhou 26
Norwalk 25
Orem 25
Hebei 24
Changsha 23
Chennai 23
Düsseldorf 23
Paris 23
Turku 23
Amsterdam 22
Brooklyn 22
Montreal 22
Denver 21
Atlanta 20
Des Moines 20
Kunming 20
Mexico City 20
Porto Alegre 20
Rio de Janeiro 20
Nairobi 19
Tashkent 19
Belo Horizonte 18
Stockholm 18
Baghdad 17
Haiphong 17
Kent 17
Fortaleza 16
Leawood 16
Poplar 16
San Francisco 16
The Dalles 16
Toronto 16
Brasília 15
Guayaquil 15
Jiaxing 15
Johannesburg 15
Millbury 15
Pune 15
Totale 9.209
Salva come PNG Salva come JPEG
Nome #
International consensus guidance for management of myasthenia gravis: Executive summary 251
Single-centre 40-year results of redo operation for recurrent thymomas. 247
Myasthenia gravis 240
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 239
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 235
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 213
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 208
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 205
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 202
Thymoma in patients with MG: characteristics and long-term outcome 198
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 195
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 193
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 193
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 189
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 186
SFEMG: A piece in the diagnostic puzzle of myasthenia 186
When myasthenia gravis is not all. 180
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 180
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 179
A Genome-wide Association Study of Myasthenia Gravis 176
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 176
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 175
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 174
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 168
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 167
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 165
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 162
Myasthenia gravis with antibodies to MuSK: an update 161
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 159
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 159
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 158
Response to therapy in myasthenia gravis with anti-MuSK antibody 157
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 155
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 154
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 151
Concordance between radioimmunoassay and fixed cell-based assay in subjects without myasthenia gravis: optimizing the diagnostic approach 149
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 148
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 148
BAFF serum levels in myasthenia gravis: effects of therapy 143
Anti-AChR-negative myasthenia gravis: clinical and immunological features 143
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 142
Determinants of cognitive impairment in elderly myasthenia gravis patients 141
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 141
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 141
Multiple paraneoplastic diseases associated with thymoma. 140
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 140
Prognostic grading after complete resection for thymic malignancies 139
Diagnostic features and subtyping of thymoma lymph node metastases 137
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 137
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 137
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 135
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 133
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 131
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 131
Immunosuppressive therapies in myasthenia gravis 130
Clinical heterogeneity of seronegative myasthenia gravis 130
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 130
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 130
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 128
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 127
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 127
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 125
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 124
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 122
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 122
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 119
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology 118
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 118
Spontaneous recovery from anti-NMDAR encephalitis 116
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 116
Acquired myasthenia gravis in childhood. 114
In sickness and in health: when myasthenia gravis is a conjugal matter 113
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 112
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 112
Thymoma recurrences in myasthenia gravis patients 111
Thymectomy in the treatment of myasthenia gravis: report of 247 patients 111
Imatinib mesylate in thymic epithelial malignancies. 110
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 109
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 109
Course and treatment of myasthenia gravis during pregnancy 108
Early-onset myasthenia gravis: clinical characteristics and response to therapy 108
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 107
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 107
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 105
Anti-MuSK antibodies: Correlation with myasthenia gravis severity 105
Benefit and danger from immunotherapy in myasthenia gravis 105
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 105
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study 104
Myasthenia gravis during interferon alfa therapy 104
Controversies in Ocular Myasthenia Gravis 104
Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report 104
A practical guide to the recognition and management of myasthenia gravis 103
Antibody-phenotype correlation in stiff-person syndrome 102
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 102
Myasthenia gravis and associated autoimmune diseases 99
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 99
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 99
Familial autoimmune myasthenia gravis: report of four families 98
Minimal manifestation status and prednisone withdrawal in the MGTX trial 98
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 97
Totale 14.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202134 0 0 0 0 0 0 0 0 0 0 0 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20252.252 54 90 181 60 171 66 72 119 376 172 455 436
2025/20266.189 954 176 358 805 1.149 302 970 288 432 439 165 151
Totale 17.666